Q3 2025 Vivoryon Therapeutics NV Earnings Call Transcript
Key Points
- Vivoryon Therapeutics NV (WBO:VVYN) presented compelling data for varoglutamstat in kidney disease, showing significant interest and excitement within the scientific and medical community.
- The company successfully completed a private placement of new shares, raising EUR5.1 million, extending their cash runway into the third quarter of 2026.
- Varoglutamstat demonstrated a consistent and meaningful treatment effect across all patients, including those with more impaired kidney functions.
- The company is exploring additional development and partnership opportunities beyond diabetic kidney disease, leveraging their platform of oral small molecule QPCT/L inhibitors.
- Vivoryon Therapeutics NV (WBO:VVYN) reported a significant reduction in net loss for the first nine months of 2025 compared to the same period in 2024, indicating improved financial management.
- The company experienced a significant decrease in cash and cash equivalents, from EUR9.4 million at the end of 2024 to EUR2.5 million by the end of September 2025.
- Research and development expenses decreased significantly, which could indicate a slowdown in clinical development activities.
- The departure of the CFO, Anne, in December 2025, could lead to potential disruptions in financial management and strategy execution.
- Despite promising data, the company still faces substantial unmet needs in the kidney disease space, indicating ongoing challenges in achieving market penetration.
- The company is still in the process of securing strategic financing and partnership opportunities, which could delay the initiation of planned Phase IIb studies.
Good day, and thank you for standing by. Welcome to the Vivoryon Therapeutics 2025 third quarter earnings call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to turn the conference over to your first speaker today, Julia Neugebauer, COO. Please go ahead.
Thank you, Rasia. Good morning or good afternoon, everyone, and thank you for joining us today for Vivoryon's third quarter 2025 results call. Earlier today, we issued a press release reporting our third quarter 2025 financial results and business update, which can be found in the Vivoryon's website at www.vivoryon.com. On the call with me today are Frank Weber, our Chief Executive Officer; Marcus Irsfeld, our acting Chief Financial Officer; as well as Michael Schaeffer, our Chief Business Officer.
Before we start, I would like to remind you that during this conference call, we will
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
